TIL

Competing (immuno)therapies are equal in costs but more effective compared to TIL which will impede uptake of TIL.

Research developments in TIL treatment (such as gene modification or selective TIL) will increase its’ effectiveness and leads to uptake of TIL

A biomarker, being able to select patients for TIL, is available which leads to TIL as one of the standard treatment options